In the genetic PDAC mouse model KPC (K-rasLSL.G12D/+; p53R172H/+; PdxCre mice) and orthotopic transplantation of KPC derived cells, MET inhibition with capmatinib sensitised PDAC tumours to gemcitabine, resulting in a reduction in primary tumour volume and metastatic burden via increased apoptosis [57]. The gene discussed is MET; the disease is neoplasm.